{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:57:50Z","timestamp":1792277870248,"version":"4.4.0"},"reference-count":119,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives\/Background<\/jats:title>\n                    <jats:p>Treatment of migraine in the setting of either renal or hepatic disease can be daunting for clinicians. Not only does the method of metabolism have to be considered, but also the method of elimination\/excretion of the parent drug and any active or toxic metabolites. Furthermore, it is difficult to think about liver or kidney disease in isolation, as liver disease can sometimes contribute to impaired renal function and renal disease can sometimes impair hepatic metabolism, through the cytochrome P450 system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A detailed search for terms related to liver disease, renal disease, and migraine management was performed in PubMed, Ovid Medline, Embase, and the Cochrane Library.For each medication, product labels were retrieved and reviewed using the US FDA website, with additional review of IBM Micromedex, LiverTox, and the Renal Drug Handbook.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This manuscript provides an overview of migraine drug metabolism and how it can be affected by liver and renal impairment. It reviews the standard terminology recommended by the US Food and Drug Administration for the different stages of hepatic and renal failure. The available evidence regarding the use of abortive and preventative medicines in the setting of organ failure is discussed in detail, including more recent therapies such as lasmiditan, gepants, and calcitonin gene\u2010related peptide antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For acute therapy, the use of NSAIDS should be limited, as these carry risk for both severe hepatic and renal disease. Triptans can be selectively used, often with dose guideline adjustments. Ubrogepant may be used in severe hepatic disease with dose adjustment and lasmiditan can be used in end stage renal disease. Though non\u2010medicine strategies may be the most reasonable initial approach, many preventative medications can be used in the setting of hepatic and renal disease, often with dose adjustment. This review provides tables of guidelines, including reduced dosing recommendations, for the use of abortive and preventative migraine medications in hepatic and renal failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14437","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:04:31Z","timestamp":1674950671000},"page":"9-24","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Narrative review of migraine management in patients with renal or hepatic disease"],"prefix":"10.1111","volume":"63","author":[{"given":"Jennifer I.","family":"Stern","sequence":"first","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6583-2188","authenticated-orcid":false,"given":"Shae","family":"Datta","sequence":"additional","affiliation":[{"name":"Department of Neurology NYU Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-7172","authenticated-orcid":false,"given":"Chia\u2010Chun","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Garza","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorice L.","family":"Vieira","sequence":"additional","affiliation":[{"name":"New York University Health Sciences Library, New York University Grossman School of Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9382-0897","authenticated-orcid":false,"given":"Carrie E.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.060"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765"},{"key":"e_1_2_7_5_1","unstructured":"https:\/\/www.micromedexsolutions.com\/"},{"key":"e_1_2_7_6_1","volume-title":"Clinical and Research Information on Drug\u2010Induced Liver Injury [Internet]","author":"LiverTox","year":"2012"},{"key":"e_1_2_7_7_1","volume-title":"The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners","year":"2019"},{"key":"e_1_2_7_8_1","first-page":"69","article-title":"Drug dosing in renal disease","volume":"32","author":"Doogue MP","year":"2011","journal-title":"Clin Biochem Rev"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00340118"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13061"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2015.10.002"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv315"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-5-77"},{"key":"e_1_2_7_14_1","first-page":"497","article-title":"Headache in pediatric and adolescent patients with chronic kidney disease and after kidney transplantation: a comparative study","volume":"37","author":"Elron E","year":"2022","journal-title":"J Child Neurol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417719235"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03025.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1972.hed1201001.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2009000600003"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00668.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP71158"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01217.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-009-0119-1"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2008.00474.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1973.51"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05242-1"},{"key":"e_1_2_7_27_1","first-page":"73","article-title":"Drug\u2010induced liver injury","volume":"6","author":"David S","year":"2010","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0553-z"},{"key":"e_1_2_7_29_1","volume-title":"Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling","year":"2003"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000034565.40011.60"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500060505"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-014-0297-2"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-014-1798-1"},{"key":"e_1_2_7_34_1","volume-title":"Micromedex Solutions","author":"Acetaminophen"},{"key":"e_1_2_7_35_1","unstructured":"Pfizer.Motrin (ibuprofen) [package insert].U.S. Food and Drug Administration. Revised April 2007. Accessed September 6 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/017463s105lbl.pdf"},{"key":"e_1_2_7_36_1","unstructured":"Atnahs Pharma.Naprosyn (naproxen) [package insert].U.S. Food and Drug Administration. Revised March 2017. Accessed September 6 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/017581s113 018164s063 020067s020lbl.pdf"},{"key":"e_1_2_7_37_1","volume-title":"Micromedex Solutions","author":"Naproxen"},{"key":"e_1_2_7_38_1","unstructured":"Glaxo Smith Kline.Amerge (naratriptan) [package insert].U.S. Food and Drug Administration. Revised November 2016. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020763s011lbl.pdf"},{"key":"e_1_2_7_39_1","unstructured":"GlaxoSmithKline.Imitrex (sumatriptan) [package insert].U.S. Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020132s028 020626s025lbl.pdf. November 2013. Accessed May 1 2022."},{"key":"e_1_2_7_40_1","unstructured":"GlaxoSmithKline.Imitrex (sumatriptan) SC [package insert].U.S. Food and Drug Administration. June 2015. Accessed September 4 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020080s049lbl.pdf"},{"key":"e_1_2_7_41_1","unstructured":"Endo Pharmaceuticals.Frova (frovatriptan) [package insert].U.S. Food and Drug Administration. Revised August 2018. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021006s022lbl.pdf"},{"key":"e_1_2_7_42_1","unstructured":"Merck and Co.Maxalt (rizatriptan) [package insert].U.S. Food and Drug Administration. Revised December 2011. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020864s011s016s017s018s019 020865s012s016s018s020s021lbl.pdf"},{"key":"e_1_2_7_43_1","unstructured":"Ortho\u2010McNeil Pharmaceuticals.Axert (almotriptan) [package insert].U.S. Food and Drug Administration. Revised April 2009. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021001s010s011lbl.pdf"},{"key":"e_1_2_7_44_1","unstructured":"AstraZeneca.Zomig (zolmitriptan). [package insert].U.S. Food and Drug Administration. Revised September 2012. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020768s019s021 021231s010s011lbl.pdf"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102497017S1803"},{"key":"e_1_2_7_46_1","unstructured":"Pfizer Pharmaceuticals.Relpax (eletriptan) [package insert].U.S. Food and Drug Administration. Revised November 2013. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021016s021s023s024s027lbl.pdf"},{"key":"e_1_2_7_47_1","unstructured":"Biohaven Pharmaceuticals.Nurtec (rimegepant) [package insert].U.S. Food and Drug Administration. Revised February 2020. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212728s000lbl.pdf"},{"key":"e_1_2_7_48_1","unstructured":"Allergan Pharmaceuticals.Ubrelvy (ubrogepant) [package insert].U.S. Food and Drug Administration. Revised December 2019. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211765s000lbl.pdf"},{"key":"e_1_2_7_49_1","unstructured":"Eli Lilly and Co.Reyvow (lasmiditan) [package insert].U.S. Food and Drug Administration. Issued March 2019. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211280s000lbl.pdf"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90046-3"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.08.039"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.03.023"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cms086"},{"key":"e_1_2_7_54_1","volume-title":"Micromedex Solutions","author":"Ibuprofen"},{"key":"e_1_2_7_55_1","unstructured":"Sandoz Inc.Amitriptyline [product information].U.S. Food and Drug Administration. Revised May 2014. Accessed September 5 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/085966s095 085969s084 085968s096 085971s075 085967s076 085970s072lbl.pdf"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12196"},{"key":"e_1_2_7_57_1","unstructured":"Patheon.Pamelor (nortriptyline) [package insert].U.S. Food and Drug Administration. Revised October 2012. Accessed September 10 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/018012s029 018013s061lbl.pdf"},{"key":"e_1_2_7_58_1","unstructured":"Wyeth.Effexor (venlafaxine) [product insert].U.S. Food and Drug Administration. Revised February 2008. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020151s051lbl.pdf"},{"key":"e_1_2_7_59_1","unstructured":"Janssen Pharmaceuticals.Topamax (topiramate) [product information].U.S. Food and Drug Administration. Revised October 2012. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020844s041lbl.pdf"},{"key":"e_1_2_7_60_1","unstructured":"Abbott Pharmaceuticals.Depakote (divalproex sodium) [package insert].U.S. Food and Drug Administration. Revised October 2011. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018723s037lbl.pdf"},{"key":"e_1_2_7_61_1","unstructured":"Pfizer.Neurontin (gabapentin) [product insert].U.S. Food and Drug Administration. Revised October 2017. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020235s064_020882s047_021129s046lbl.pdf"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.09.030"},{"key":"e_1_2_7_63_1","unstructured":"Wyeth Pharmaceuticals.Inderal (propranolol) [product information].U.S. Food and Drug Administration. Revised November 2010. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016418s080 016762s017 017683s008lbl.pdf"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974165part1761"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2007.07.003"},{"key":"e_1_2_7_66_1","unstructured":"Novartis Pharmaceuticals.Lopressor (metoprolol) [product insert].U.S. Food and Drug Administration. Revised February 2008. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/017963s062018704s021lbl.pdf"},{"key":"e_1_2_7_67_1","unstructured":"AstraZeneca.Atacand (candesartan) [package insert].U.S. Food and Drug Administration. Revised February 2015. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020838s036lbl.pdf"},{"key":"e_1_2_7_68_1","unstructured":"AstraZeneca Pharmaceuticals.Zestril (lisinopril) [package insert].U.S. Food and Drug Administration. Revised March 2012. Accessed August 26 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019777s054lbl.pdf"},{"key":"e_1_2_7_69_1","unstructured":"Pfizer.Calan SR (verapamil) [package insert].U.S. Food and Drug Administration. Revised September 2017. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/019152s041lbl.pdf"},{"key":"e_1_2_7_70_1","unstructured":"Allergan.Botox (onabotulinumtoxin A) [package insert].U.S. Food and Drug Administration. Revised April 2017. Accessed May 1 2022.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103000s5302lbl.pdf"},{"key":"e_1_2_7_71_1","unstructured":"AbbVie.Qulipta (atogepant) [package insert]. Revised September 2021. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf"},{"key":"e_1_2_7_72_1","unstructured":"Amgen Pharmaceuticals.Aimovig (erenumab) [package insert].U.S. Food and Drug Administration. Revised February 2021. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf"},{"key":"e_1_2_7_73_1","unstructured":"Eli Lilly and Company.Emgality (galcanezumab) [package insert].U.S. Food and Drug Administration. Revised June 2019. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761063s003lbl.pdf"},{"key":"e_1_2_7_74_1","unstructured":"Teva Pharmaceuticals USA.Ajovy (fremanezumab) [package insert].U.S. Food and Drug Administration. Revised January 2020. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761089s002lbl.pdf"},{"key":"e_1_2_7_75_1","unstructured":"Lundbeck Pharmaceuticals.Vyepti (eptinezumab) [package insert].U.S. Food and Drug Administration. Revised February 2020. Accessed May 1 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761119s000lbl.pdf"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.011"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000646"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12324"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0534"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.10.1604"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.04.015"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12560"},{"key":"e_1_2_7_84_1","unstructured":"Acetaminophen [package insert] [online]. Accessed August 27 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204767s000lbl.pdf"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i45.5651"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831030-00007"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.2.270"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542162"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.737"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2008.00204.x"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.42.s2.3.x"},{"key":"e_1_2_7_93_1","unstructured":"Serotonin receptor agonists (triptans) [online]. Accessed August 20 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13510"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfaa093"},{"key":"e_1_2_7_96_1","unstructured":"Rimegepant from: LiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury by National Institute of Diabetes and Digestive and Kidney Diseases [online]. Accessed August 20 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12728"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"e_1_2_7_99_1","volume-title":"Micromedex Solutions","author":"Amitriptyline"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12925"},{"key":"e_1_2_7_101_1","volume-title":"Micromedex Solutions","author":"Nortriptyline"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2005.12.009"},{"key":"e_1_2_7_103_1","unstructured":"Lisinopril [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548860\/"},{"key":"e_1_2_7_104_1","unstructured":"Amitriptyline [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548410\/"},{"key":"e_1_2_7_105_1","unstructured":"Nortriptyline [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548526\/"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2000.tb11932.x"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.13.9.697"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31826af296"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-5-200003070-00016"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-11-199906010-00014"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197904263001706"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1017\/S031716710003482X"},{"key":"e_1_2_7_113_1","unstructured":"Topiramate [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/"},{"key":"e_1_2_7_114_1","unstructured":"Erenumab [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548079\/"},{"key":"e_1_2_7_115_1","unstructured":"Galcanezumab [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548140\/"},{"key":"e_1_2_7_116_1","unstructured":"Fremanezumab [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548782\/"},{"key":"e_1_2_7_117_1","unstructured":"Eptinezumab [LiverTox online]. Accessed August 21 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572292\/"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.916"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2016.02.001"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14437","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14437","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:00:10Z","timestamp":1762081210000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/head.14437"],"URL":"https:\/\/doi.org\/10.1111\/head.14437","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}